TWI536998B - A use of an extract of zingiber zerumbet thereof - Google Patents
A use of an extract of zingiber zerumbet thereof Download PDFInfo
- Publication number
- TWI536998B TWI536998B TW104104579A TW104104579A TWI536998B TW I536998 B TWI536998 B TW I536998B TW 104104579 A TW104104579 A TW 104104579A TW 104104579 A TW104104579 A TW 104104579A TW I536998 B TWI536998 B TW I536998B
- Authority
- TW
- Taiwan
- Prior art keywords
- red ball
- ball ginger
- sample
- red
- ginger extract
- Prior art date
Links
- 240000000451 Zingiber zerumbet Species 0.000 title description 2
- 235000014687 Zingiber zerumbet Nutrition 0.000 title description 2
- 229940002508 ginger extract Drugs 0.000 claims description 48
- 235000020708 ginger extract Nutrition 0.000 claims description 48
- 241000234314 Zingiber Species 0.000 claims description 39
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 39
- 235000008397 ginger Nutrition 0.000 claims description 39
- 239000000052 vinegar Substances 0.000 claims description 26
- 235000021419 vinegar Nutrition 0.000 claims description 26
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000007164 Oryza sativa Nutrition 0.000 claims description 9
- 235000009566 rice Nutrition 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000583531 Alpinia purpurata Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000010411 cooking Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000001174 ascending effect Effects 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 32
- 206010012601 diabetes mellitus Diseases 0.000 description 27
- 230000002207 retinal effect Effects 0.000 description 15
- 229930003935 flavonoid Natural products 0.000 description 13
- 235000017173 flavonoids Nutrition 0.000 description 13
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 241000209094 Oryza Species 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- -1 flavonoid compound Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- JFOWDKWFHZIMTR-RUCXOUQFSA-N (2s)-2-aminopentanedioic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(O)=O JFOWDKWFHZIMTR-RUCXOUQFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NPUVYHNDWLTMSW-UHFFFAOYSA-N OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.[AsH3].[AsH3] Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.[AsH3].[AsH3] NPUVYHNDWLTMSW-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
本發明係關於一種紅球薑萃取物之用途,特別係一種紅球薑萃取物用以製備改善糖尿病視網膜病變藥物之用途。 The invention relates to the use of a red ball ginger extract, in particular to a red ball ginger extract for preparing a medicament for improving diabetic retinopathy.
糖尿病視網膜病變(diabetic retinopathy)為糖尿病(diabetes)的一種併發症,其係由於高血糖所誘導之血管壁機能不全,因而影響血管一視網膜屏障(blood-retinal barrier)之功能及提升患部血管之通透性等視網膜微循環(capillary circulation)的改變所造成之症狀,此為糖尿病患者致盲的主要原因。 Diabetic retinopathy (diabetic retinopathy) is a complication of diabetes, which is caused by hyperglycemia-induced vascular wall insufficiency, thus affecting the function of the blood-retinal barrier and enhancing the blood vessels of the affected part. Symptoms caused by changes in retinal microcirculation, such as permeability, are the leading cause of blindness in diabetic patients.
習用治療糖尿病視網膜病變之方法包含雷射手術、玻璃體切除術(vitrectomy)及眼部注射皮質類固醇(cprtocpsterpod)等方法,惟三者均屬於侵入性醫療行為,且仍無法達到根治之效果,患者仍需隨時監控自己的血糖,並使自己的血糖維持在正常範圍(euglycemia),而皮質類固醇之投藥更可能造成副作用之發生。據此,習用治療糖尿病視網膜病變之方法仍有改善之必要。 Methods for the treatment of diabetic retinopathy include laser surgery, vitrectomy, and ocular injection of corticosteroids (cprtocpsterpod). All three are invasive medical behaviors, and still cannot achieve the effect of radical cure. You need to monitor your blood sugar at any time and keep your blood sugar in the normal range (euglycemia), and the administration of corticosteroids is more likely to cause side effects. Accordingly, there is still a need for improved methods for treating diabetic retinopathy.
本發明係提供一種紅球薑萃取物之用途,係作為改善糖尿病視網膜病變之活性成份,以改善習用治療糖尿病視網膜病變之方法所造成之副作用者。 The present invention provides a use of a red ball ginger extract as an active ingredient for improving diabetic retinopathy to improve the side effects caused by the conventional method for treating diabetic retinopathy.
一種紅球薑萃取物之用途,係應用於製備改善糖尿病視網膜病變的藥物,該紅球薑萃取物係投予一所需生物體,以改善該所需升物體 之糖尿病視網膜病變現象,其中,該紅球薑萃取物係由如下述之紅球薑萃取物的製備方法製得:將一紅球薑樣品浸漬於米醋中8小時,獲得一浸漬紅球薑樣品;將該浸漬紅球薑樣品以95~105℃之溫度、1.5~2.5kg/m2之壓力下蒸煮30分鐘,獲得一醋炙紅球薑樣品;及於70~90℃之溫度下,以一萃取溶劑萃取該醋炙紅球薑樣品8小時,該萃取溶劑為純水或體積百分濃度為95%之一乙醇溶液,以獲得該紅球薑萃取物。 The use of a red ball ginger extract for the preparation of a medicament for improving diabetic retinopathy, wherein the red ball ginger extract is administered to a desired organism to improve the diabetic retinopathy of the desired ascending object, wherein The red ball ginger extract is prepared by the following method for preparing red ball ginger extract: a red ball ginger sample is immersed in rice vinegar for 8 hours to obtain a sample of impregnated red ball ginger; the impregnated red ball ginger sample The vinegar red ball ginger sample is obtained by boiling at a temperature of 95-105 ° C and a pressure of 1.5-2.5 kg/m 2 for 30 minutes; and extracting the vinegar red with an extraction solvent at a temperature of 70-90 ° C The ginger sample was incubated for 8 hours, and the extraction solvent was pure water or a 95% by volume ethanol solution to obtain the red ball ginger extract.
本發明之紅球薑萃取物之用途,其中,該紅球薑萃取物係以每天每公斤所需個體體重600毫克之劑量投予該所需個體,且連續投予28天。 The use of the red ball ginger extract of the present invention, wherein the red ball ginger extract is administered to the desired individual at a dose of 600 mg per kg of the desired individual per day, and is administered continuously for 28 days.
本發明之紅球薑萃取物之用途,係以富含有類黃酮化合物之紅球薑萃取物作為改善糖尿病視網膜病變之活性成份,防止習用藥物所導致之副作用的衍生,為本發明之功效。 The use of the red ball ginger extract of the present invention is a derivative of the red globin extract rich in flavonoid compound as an active ingredient for improving diabetic retinopathy, and preventing the side effects caused by conventional drugs, and is an effect of the present invention.
第1a圖:係本試驗第C0組糖尿病大鼠之眼底攝影(fundus photography)結果。 Figure 1a: Results of fundus photography of group C0 diabetic rats in this test.
第1b圖:係本試驗第C0組糖尿病大鼠之視網膜PAS、蘇木精染色結果。 Figure 1b: Results of PAS and hematoxylin staining in the retina of group C0 diabetic rats in this test.
第2a圖:係本試驗第C1組糖尿病大鼠之眼底攝影(fundus photography)結果。 Figure 2a: Results of fundus photography of Group C1 diabetic rats in this trial.
第2b圖:係本試驗第C1組糖尿病大鼠之視網膜PAS、蘇木精染色結果。 Figure 2b: Results of PAS and hematoxylin staining in the retina of the C1 group of diabetic rats.
第3a圖:係本試驗第C2組糖尿病大鼠之眼底攝影(fundus photography)結果。 Figure 3a: Results of fundus photography of Group C2 diabetic rats in this trial.
第3b圖:係本試驗第C2組糖尿病大鼠之視網膜PAS、蘇木精染色結 果。 Figure 3b: Retinal PAS and hematoxylin staining in group C2 diabetic rats fruit.
第4a圖:係本試驗第C3組糖尿病大鼠之眼底攝影(fundus photography)結果。 Figure 4a: Results of fundus photography of Group C3 diabetic rats in this trial.
第4b圖:係本試驗第C3組糖尿病大鼠之視網膜PAS、蘇木精染色結果。 Figure 4b: Results of PAS and hematoxylin staining in the retina of group C3 diabetic rats.
第5a圖:係本試驗第C4組糖尿病大鼠之眼底攝影(fundus photography)結果。 Figure 5a: Results of fundus photography of Group C4 diabetic rats in this trial.
第5b圖:係本試驗第C4組糖尿病大鼠之視網膜PAS、蘇木精染色結果。 Figure 5b: Results of PAS and hematoxylin staining in the retina of group C4 diabetic rats in this test.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下: 本發明所述之「紅球薑樣品」係指紅球薑(Zingiber zerumbet)之塊莖(rhizome),常被作為調味料及開味食材,可以用以治療牙痛、消化不良、腹瀉等症狀,亦具有促進血液循環之活性。 The above and other objects, features and advantages of the present invention will become more <RTIgt;"Gingersample" refers to the rhizome of Zingiber zerumbet , which is often used as a seasoning and flavoring ingredient. It can be used to treat symptoms such as toothache, indigestion, diarrhea, and also promote blood circulation.
本發明之紅球薑萃取物係萃取自一紅球薑樣品,同時藉由米醋之浸漬及高溫蒸煮,使該紅球薑樣品所含有之類黃酮化合物容易於萃取過程中釋出,使該紅球薑萃取物富含類黃酮化合物,進而可以利用該些類黃酮化合物修復高血糖所導致之視網膜細胞的損傷現象。 The red ball ginger extract of the invention is extracted from a red ball ginger sample, and the flavonoid compound contained in the red ball ginger sample is easily released during the extraction process by impregnation with rice vinegar and high temperature cooking, so that the red Ginger extract is rich in flavonoids, which in turn can be used to repair damage to retinal cells caused by hyperglycemia.
詳而言之,本發明之一實施例的紅球薑萃取物係可以藉由包含以下步驟之方法製備獲得:提供如上述之紅球薑樣品,將該紅球薑樣品浸漬於米醋,續進行高溫蒸煮,以獲得一醋炙紅球薑樣品,另萃取該醋炙紅球薑樣品,即可以獲得該紅球薑萃取物。 In detail, the red ball ginger extract of one embodiment of the present invention can be obtained by a method comprising the steps of: providing a red ball ginger sample as described above, immersing the red ball ginger sample in rice vinegar, and continuing The red ball ginger extract can be obtained by cooking at a high temperature to obtain a sample of vinegar red ball ginger and extracting the vinegar red ball ginger sample.
該紅球薑樣品係可以於去除其表面之雜質後,浸漬於米醋之中,以避免該紅球薑樣品表面之雜質對後續步驟造成影響。於本實施例中, 係將該紅球薑樣品置於一封閉容器中,以防止於浸漬過程中有外界雜質進入,如此,米醋即可以悶透滲入該紅球薑樣品,以形成一浸漬紅球薑樣品。舉例而言,本實施例係取得50kg之紅球薑新鮮塊根,洗淨去除泥土後,切片、陰乾以獲得5.3kg之紅球薑樣品(含水量為89.4%),並取5kg之紅球薑樣品浸漬於5L之米醋中8小時,即可以獲得該浸漬紅球薑樣品。 The red ball ginger sample can be immersed in rice vinegar after removing impurities on the surface thereof to avoid impurities on the surface of the red ball ginger sample from affecting the subsequent steps. In this embodiment, The red ball ginger sample is placed in a closed container to prevent foreign matter from entering during the impregnation process, so that the rice vinegar can be smothered into the red ball ginger sample to form a sample of the impregnated red ball ginger. For example, in this embodiment, fresh roots of 50 kg of red ball ginger are obtained, washed and removed, and sliced and dried to obtain a 5.3 kg sample of red ginger (water content: 89.4%), and 5 kg of red ball ginger is taken. The sample was immersed in 5 L of rice vinegar for 8 hours to obtain the impregnated red ball ginger sample.
續將該浸漬紅球薑樣品置於一密閉空間(例如一壓力鍋)內,並於95~105℃之溫度、1.5~2.5kg/cm2之壓力下進行蒸煮30分鐘,直至該浸漬紅球薑樣品外觀呈現黑褐色,可以判斷該浸漬紅球薑樣品已被蒸透,即獲得一醋炙紅球薑樣品。該醋炙紅球薑樣品另可以經由冷凍乾燥,使該醋炙紅球薑樣品之含水量降至10%以下,以利於該醋炙紅球薑樣品之保存。 Continue to place the impregnated red ball ginger sample in a confined space (for example, a pressure cooker), and cook at a temperature of 95-105 ° C and a pressure of 1.5-2.5 kg/cm 2 for 30 minutes until the impregnated red ball ginger The appearance of the sample is dark brown, and it can be judged that the sample of the impregnated red ball ginger has been vaporized, that is, a sample of vinegar red ball ginger is obtained. The vinegar red ball ginger sample can be further freeze-dried to reduce the water content of the vinegar red ball ginger sample to less than 10% to facilitate the preservation of the vinegar red ball ginger sample.
該醋炙紅球薑樣品另可以經由一萃取溶劑之萃取,以獲得該紅球薑萃取物。該萃取溶劑可以選擇為選擇為純水,或是體積百分濃度為95%之一乙醇溶液,使該醋炙紅球薑樣品所富含之黃酮類化合物得以釋出於該萃取溶劑中,以獲得該紅球薑萃取物。於本實施例中,係取500克之醋炙紅球薑樣品,以1公升之純水或該乙醇溶液,於70~90℃定溫回流8小時,重複萃取3次,最後藉由真空過濾、減壓濃縮及冷凍乾燥,以獲得該該紅球薑萃取物。 The vinegar red ball ginger sample can be further extracted by an extraction solvent to obtain the red ball ginger extract. The extraction solvent may be selected to be pure water or a 95% by volume ethanol solution, so that the flavonoids rich in the vinegar red ginger sample are released into the extraction solvent. The red ball ginger extract was obtained. In this embodiment, 500 grams of vinegar red ball ginger sample is taken, and 1 liter of pure water or the ethanol solution is refluxed at 70-90 ° C for 8 hours, and the extraction is repeated 3 times, and finally by vacuum filtration, The mixture was concentrated under reduced pressure and lyophilized to obtain the red ginger extract.
本發明之紅球薑萃取物係可以有效修復高血糖所導致之視網膜細胞的損傷現象,因而係能夠作為一種改善糖尿病視網膜病變之活性成分,例如可以將該紅球薑萃取物應用於製備改善糖尿病視網膜病變之藥物或保健食品,該紅球薑萃取物與醫藥學上可以接受之載劑或賦形劑組合形成一醫藥組合物,其中,該紅球薑萃取物係可以製備成任何方便食用之型式,如錠劑、膠囊、粉劑、粒劑或液劑等,或者將該紅球薑萃取物與其他食品或飲料組合,以一適於食用之樣態供生物體以口服方式服用。 The red ball ginger extract of the invention can effectively repair the damage of retinal cells caused by hyperglycemia, and thus can be used as an active ingredient for improving diabetic retinopathy, for example, the red ball ginger extract can be applied to prepare and improve diabetes. A drug or health food for retinopathy, the red ball ginger extract is combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, wherein the red ball ginger extract can be prepared for any convenient consumption. The formula, such as a tablet, a capsule, a powder, a granule or a liquid, or the like, or the red ball ginger extract is combined with other foods or beverages, and is administered to the organism in an edible form for oral administration.
又,該紅球薑萃取物係可以供投予一所需個體,例如以每天每公斤之所需個體體重投予600mg之紅球薑萃取物,且連續投予該所需個體28天,使黃酮類化合物等活性成分得以於該所需個體體內作用,而可以改善該所需個體之糖尿病視網膜病變現象。 Further, the red ball ginger extract can be administered to a desired individual, for example, 600 mg of red ball ginger extract per kilogram of the desired individual body weight per day, and the desired individual is continuously administered for 28 days. The active ingredient such as a flavonoid can act in the desired individual to improve the diabetic retinopathy of the desired individual.
為證實本發明紅球薑萃取物確實具有改善糖尿病視網膜病變現象之活性,遂進行以下試驗: In order to confirm that the red ball ginger extract of the present invention does have an activity of improving the phenomenon of diabetic retinopathy, the following tests were carried out:
(A)紅球薑萃取物之製備及活性成分含量檢測(A) Preparation of red ball ginger extract and detection of active ingredient content
請參照第1表所示,各組紅球薑萃取物之製備方法係如上所述,各取500克之紅球薑樣品或醋炙紅球薑樣品,以1公升之萃取溶劑進行萃取後,經由過濾、濃縮及冷凍乾燥後,以獲得各組之紅球薑萃取物。 Please refer to Table 1, the preparation method of each group of red ball ginger extract is as described above, each 500 grams of red ball ginger sample or vinegar red ball ginger sample, extracted with 1 liter of extraction solvent, after After filtration, concentration and lyophilization, each group of red ball ginger extract was obtained.
類黃酮化合物(flavonoids)的含量測定,係以槲黃素(quercetin)作為標準品,利用其濃度及吸光值製成標準曲線。分別將氯化鋁水溶液(2%,1mL)加入該槲黃素標準品(濃度範圍為1~100mg/mL,1mL)與各組之紅球薑萃取物(濃度為1~100mg/mL,1mL)中,於室溫下靜置10分鐘後,量測於430nm波長下之吸光值,並依據吸光值量測結果回推各組紅球薑萃取物所含有之類黃酮類化合物的含量(以〝每克紅球薑萃取物所含有之槲黃素含量〞作為比較基準),紀錄於第2表。 The content of flavonoids was determined by using quercetin as a standard, and its concentration and absorbance were used to prepare a standard curve. Aqueous aluminum chloride solution (2%, 1 mL) was added to the flavin standard (concentration range: 1 to 100 mg/mL, 1 mL) and the red ball ginger extract of each group (concentration: 1 to 100 mg/mL, 1 mL). In the case of standing at room temperature for 10 minutes, measuring the absorbance at a wavelength of 430 nm, and pushing back the content of the flavonoids contained in each group of red ginger extract according to the absorbance measurement result ( The content of quercetin contained in grams of red ball ginger extract is used as a benchmark. It is recorded in Table 2.
第2表、本試驗各組紅球薑萃取物之類黃酮類化合物的含
量。
請參照第2表所示,根據上述試驗結果,藉由將該紅球薑樣品浸漬於米醋,續經過高溫蒸煮,使該紅球薑樣品所含有之類黃酮化合物容易於萃取過程中釋出,溶解於該萃取溶劑(即,純水或該酒精溶液)中,而可以獲得富含有類黃酮類化合物之紅球薑萃取物。 Referring to the results of the above test, according to the above test results, the red ball ginger sample is immersed in rice vinegar, and then subjected to high temperature cooking, so that the flavonoid compound contained in the red ball ginger sample is easily released during the extraction process. It is dissolved in the extraction solvent (i.e., pure water or the alcohol solution) to obtain a red ball ginger extract rich in flavonoids.
(B)對高血糖所導致損傷之視網膜細胞的存活影響(B) Survival effects on retinal cells caused by hyperglycemia
本試驗係選用視網膜細胞(ARPE-19cells),購自食品工業發展研究所,該視網膜細胞係培養於含有1.2g/L碳酸氫鈉(sodium bicarbonate)、2.5mM L-麩氨酸(L-Glutamine)、15mM 4-羥乙基乙磺酸(HEPES)、0.5mM丙酮酸鈉(sodium pyruvate)及10%胎牛血清(FBS)之DME/F-12(1:1)培養液中,並置於溫度為37℃、二氧化碳濃度為5%及溼度為95%之培養箱中,每隔兩天更換一次新鮮培養液。 This experiment used retinal cells (ARPE-19cells) purchased from the Food Industry Development Institute. The retinal cell line was cultured with 1.2 g/L sodium bicarbonate and 2.5 mM L -glutamate ( L- Glutamine). ), 15 mM 4-hydroxyethylethanesulfonic acid (HEPES), 0.5 mM sodium pyruvate and 10% fetal bovine serum (FBS) in DME/F-12 (1:1) medium and placed in The fresh culture solution was changed every two days in an incubator at 37 ° C, a carbon dioxide concentration of 5%, and a humidity of 95%.
該視網膜細胞於繼代培養時,係先將培養液及細胞以1000rpm離心5分鐘,去除上清液後,再加入新的培養液,並且使10公分培養皿中維持細胞數為約1×105至1×106cells/mL。 When the retinal cells are subcultured, the culture solution and the cells are centrifuged at 1000 rpm for 5 minutes, the supernatant is removed, a new culture solution is added, and the number of cells maintained in the 10 cm culture dish is about 1×10. 5 to 1 × 10 6 cells/mL.
本試驗進行時,係可以取出已經長8~9分滿之上述視網膜細胞的10公分培養皿,去除已變色之培養液,以8mL之PBS緩衝溶液沖洗細胞一次,加入胰蛋白酶/乙二胺乙酸(Trypsin/EDTA)反應1~3分鐘後,輕搖培養皿使細胞自壁上脫落,加入已回溫的培養液,輕輕將細胞沖 散,再將含細胞之培養液分別置入離心管內,以1500rpm離心10分鐘,除去上清液後,再加入含血清之培養液,使細胞分散均勻,並取出20μL之細胞,加入20μL 0.04%之錐蟲藍(Trypan Blue)進行染色,放入細胞計數器,並於顯微鏡下計數活細胞數,細胞存活率必須不小於85%才可以進行後續試驗。 When the test is carried out, the 10 cm culture dish of the above retinal cells which has been 8 to 9 minutes old can be taken out, the discolored culture medium is removed, the cells are washed once with 8 mL of PBS buffer solution, and trypsin/ethylenediamine acetic acid is added. (Trypsin/EDTA) After 1~3 minutes of reaction, gently shake the culture dish to make the cells fall off the wall, add the warmed culture medium, and gently pour the cells. Disperse, then place the cell-containing culture solution into a centrifuge tube, centrifuge at 1500 rpm for 10 minutes, remove the supernatant, then add the serum-containing medium to disperse the cells evenly, and take 20 μL of the cells, add 20 μL 0.04 Trypan Blue was stained, placed in a cell counter, and the number of viable cells was counted under a microscope. The cell viability must be no less than 85% before subsequent experiments can be performed.
以含血清之培養液將上述視網膜細胞之濃度調整為1x105cell/mL,並且各取100μL之視網膜細胞接種於96孔盤,使每個槽孔含有1x104細胞,並於溫度為37℃、二氧化碳濃度為5%之培養箱進行隔夜培養。 The concentration of the above retinal cells was adjusted to 1×10 5 cells/mL with a serum-containing culture solution, and 100 μL of each retinal cell was seeded in a 96-well plate, so that each well contained 1×10 4 cells at a temperature of 37° C. Incubate overnight in an incubator with a carbon dioxide concentration of 5%.
經過24小時培養後,分別如第3表所示,加入葡萄糖水溶液(使最終濃度為6mM)及100μL之紅球薑萃取物(濃度為1mg/mL,溶於DMSO中),混合均勻後,於溫度為37℃,二氧化碳濃度為5%之培養箱續隔夜培養24小時。 After 24 hours of incubation, as shown in Table 3, add glucose aqueous solution (to a final concentration of 6 mM) and 100 μL of red ball ginger extract (concentration of 1 mg / mL, dissolved in DMSO), and mix well, then Incubators with a temperature of 37 ° C and a carbon dioxide concentration of 5% were cultured overnight for 24 hours.
24小時後,移除培養液,以磷酸緩衝液沖洗後,再加入100μL含有CCK-8之新鮮培養液,置於溫度為37℃,二氧化碳濃度為5%之培養箱反應2小時後,震搖5分鐘後,偵測每個槽孔於450nm波長下之吸光 值,並依未經任何藥物處理之控制組的吸光值結果計算存活率,紀錄於第4表。存活率之換算公式:「各組之吸光值」/「未經任何藥物處理之控制組吸光值」×100%。 After 24 hours, the culture solution was removed, rinsed with phosphate buffer, and then 100 μL of fresh culture medium containing CCK-8 was added and placed in an incubator at a temperature of 37 ° C and a carbon dioxide concentration of 5% for 2 hours. After 5 minutes, the absorption of each slot at 450 nm is detected. The survival rate was calculated from the absorbance values of the control group without any drug treatment and is recorded in Table 4. The conversion formula for survival rate: "absorbance value of each group" / "absorbance value of control group without any drug treatment" × 100%.
請參照第4表所示,依據上述試驗結果,萃取自該醋炙紅球薑樣品之紅球薑萃取物(即,第B5、B6組)確實具有修復高血糖所導致之視網膜細胞的損傷現象之能力。 Please refer to Table 4, according to the above test results, the red ball ginger extract extracted from the vinegar red ball ginger sample (ie, group B5, B6) does have the damage of retinal cells caused by repairing hyperglycemia. Ability.
(C)對糖尿病大鼠之糖尿病視網膜病變的影響(C) Effects on diabetic retinopathy in diabetic rats
本試驗係選用購自財團法人國家實驗研究院國家實驗動物中心之Wistar雄性大鼠,該些大鼠皆在8週週齡以上,體重介於160~180克之間。該些大鼠係飼養於大仁科技大學動物中心,維持室溫為25±1℃之動物室,光照時間與黑暗時間各為12小時,該些大鼠可以自由進食及飲水。 In this experiment, Wistar male rats purchased from the National Experimental Animal Center of the National Experimental Research Institute of the Foundation were selected. The rats were all over 8 weeks old and weighed between 160 and 180 grams. The rats were housed in the Animal Center of Darien University of Science and Technology, and maintained in an animal room at room temperature of 25 ± 1 ° C. The light time and dark time were each 12 hours. The rats were free to eat and drink.
使該些大鼠於空腹72小時後,以腹腔注射(intraperitioneal injection)方式將鏈脲佐菌素(streptozotocin,簡稱STZ)投予該些大鼠(投予劑量為60mg/kg),以誘導形成糖尿病大鼠,續於72小時後,量測該些大鼠之血糖值,血糖值高於300mg/L,且出現三多症狀(多吃、多喝、多 尿)之大鼠即可以視為成功誘導為第一型糖尿病大鼠。 After 72 hours of fasting the rats, streptozotocin (STZ) was administered to the rats by intraperitoneal injection (administered at a dose of 60 mg/kg) to induce formation. Diabetic rats, after 72 hours, measured the blood sugar levels of the rats, blood sugar levels higher than 300mg / L, and there are more than three symptoms (eat more, drink more, more Rats with urine can be considered to be successfully induced into type 1 diabetic rats.
分別將如第5表所示之紅球薑萃取物經口餵食該些糖尿病大鼠,每天餵食2次,連續餵食28天,於實驗前(第0天)及實驗後(第28天)分別量測該些糖尿病大鼠之眼壓及視網膜狀態之評估。 The diabetic rats were orally fed with the red ball ginger extract as shown in Table 5, fed twice a day for 28 days, before the experiment (day 0) and after the experiment (day 28). The assessment of intraocular pressure and retinal status of these diabetic rats was measured.
請參照第6表所示,各組糖尿病大鼠經乙醚麻醉後,分別量測第0天及第28天之各組糖尿病大鼠的眼壓,另於第28天時,點入硫酸阿托平(atropine,0.25%)點眼液後,以乙醚麻醉各組糖尿病大鼠,並於5分鐘後以眼底鏡(MiiS Horus Scope DOC100)進行各組糖尿病大鼠之眼底攝影,續犧牲各組糖尿病大鼠,將視網膜進行組織切片,並以PAS及蘇木精(periodic acid-Schiff/hematoxylin)進行染色。 Please refer to the sixth table. After the anesthesia of each group of diabetic rats, the intraocular pressure of each group of diabetic rats on the 0th day and the 28th day was measured, and on the 28th day, the arsenic sulfate was added. After atropine (0.25%) eye drops, each group of diabetic rats was anesthetized with ether, and after 5 minutes, fundus photography of each group of diabetic rats was performed with an ophthalmoscope (MiiS Horus Scope DOC100), and sacrificed for each group of diabetes. In the rat, the retina was sectioned and stained with PAS and periodic acid-Schiff/hematoxylin.
請參照第6表所示,第C0組糖尿病大鼠之眼壓持續上升,而連續餵食萃取自該醋炙紅球薑樣品之紅球薑萃取物(即,第C3、C4組)之眼壓則有顯著的下降,其眼壓下降之趨勢與第2表所示之類黃酮類化合物的含量呈正相關。 Please refer to the sixth table, the intraocular pressure of the group C0 diabetic rats continued to rise, and the intraocular pressure of the red ball ginger extract (ie, group C3, C4) extracted from the vinegar red ball ginger sample was continuously fed. There was a significant decrease, and the trend of decreased intraocular pressure was positively correlated with the content of flavonoids shown in Table 2.
續請參照第1a圖所示,該糖尿病大鼠之視網膜出現新生微細微血管,且眼部有血液滲出於眼球玻璃體(vitreous humour),且另請參照第1b圖所示,該糖尿病大鼠之視網膜另有瀰漫性蛋白質樣纖維素物質(diffused fibrinogen-like protein)蓄積及覆蓋,亦有出現細胞水腫、出血、血管擴張及血管新生的狀況;而連續餵食萃取自該醋炙紅球薑樣品之紅球薑萃取物(即,第C3、C4組)之糖尿病大鼠之視網膜病變情形有緩和的現象,顯示本發明之紅球薑萃取物確實可以改善糖尿病視網膜病變的情形,亦即,藉由米醋之浸漬及高溫蒸煮所釋出之類黃酮化合物確實可以修復高血糖所導致之視網膜細胞的損傷現象。 Continued, as shown in Figure 1a, the diabetic rat has retinal micro-vessels in the retina, and blood in the eye seeps out of the vitreous humour, and please refer to Figure 1b for the retina of the diabetic rat. There is also a diffuse fibrinogen-like protein accumulation and coverage, as well as cell edema, hemorrhage, vasodilation and angiogenesis; and continuous feeding from the vinegar red ball ginger sample red The retinopathy of diabetic rats in the ball ginger extract (ie, group C3, C4) has a mildening phenomenon, indicating that the red ball ginger extract of the present invention can indeed improve the condition of diabetic retinopathy, that is, by rice vinegar The flavonoids released by impregnation and high-temperature cooking can indeed repair the damage of retinal cells caused by hyperglycemia.
本發明之紅球薑萃取物之用途,係以富含有類黃酮化合物之紅球薑萃取物作為改善糖尿病視網膜病變之活性成份,防止習用藥物所導致之副作用的衍生,為本發明之功效。 The use of the red ball ginger extract of the present invention is a derivative of the red globin extract rich in flavonoid compound as an active ingredient for improving diabetic retinopathy, and preventing the side effects caused by conventional drugs, and is an effect of the present invention.
雖然本發明已利用上述較佳實施例揭示,然其並非用以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 While the invention has been described in connection with the preferred embodiments described above, it is not intended to limit the scope of the invention. The technical scope of the invention is protected, and therefore the scope of the invention is defined by the scope of the appended claims.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104104579A TWI536998B (en) | 2015-02-11 | 2015-02-11 | A use of an extract of zingiber zerumbet thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104104579A TWI536998B (en) | 2015-02-11 | 2015-02-11 | A use of an extract of zingiber zerumbet thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI536998B true TWI536998B (en) | 2016-06-11 |
TW201628638A TW201628638A (en) | 2016-08-16 |
Family
ID=56755825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104104579A TWI536998B (en) | 2015-02-11 | 2015-02-11 | A use of an extract of zingiber zerumbet thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI536998B (en) |
-
2015
- 2015-02-11 TW TW104104579A patent/TWI536998B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201628638A (en) | 2016-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zou et al. | Protective effect of total flavonoids extracted from the leaves of Murraya paniculata (L.) Jack on diabetic nephropathy in rats | |
EP1902722B1 (en) | Agent for elevating adiponectin concentration | |
JP6947924B2 (en) | Injectable formulation of Prusatilla saponin B4 | |
CN107468898A (en) | A kind of diabetic's special food and preparation method thereof | |
CN113262247A (en) | Pharmaceutical composition for preventing or treating diabetic complications and angioedema comprising natural mixture extract as active ingredient | |
CN103168882A (en) | Health-care tea beneficial to reducing blood glucose and slowing down diabetic complications | |
García-Cerrillo et al. | Antioxidant effects of Eryngium carlinae in diabetic rats | |
US20220133763A1 (en) | Composition containing nicotinamide mononucleotide and mogroside, and application thereof | |
Wang et al. | Exogenous biliverdin improves the function of lung grafts from brain dead donors in rats | |
Zaidun et al. | Effects of naringenin on vascular changes in prolonged hyperglycaemia in fructose-STZ diabetic rat model | |
KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
TWI536998B (en) | A use of an extract of zingiber zerumbet thereof | |
CN103599340B (en) | Pharmaceutical composition used for treating and preventing diabetes and eye complications thereof, and applications of the pharmaceutical composition | |
US20100196540A1 (en) | Foodstuff of tablets or capsules | |
US20180117109A1 (en) | Method of using cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress | |
CN112933120B (en) | Application of kauri pine extract in preparing product for resisting non-alcoholic fatty liver disease | |
JP2014239699A (en) | Blood adiponectin amount increasing agent | |
KR20160039733A (en) | Composition for preventing or treating liver diseases comprising sonicated ginseng berry | |
KR20150118689A (en) | Composition including Dendropanax morbifera extracts for prevention or treatment of hyper-proliferative and migratory diseases by vascular smooth muscle cells | |
JP2009137920A (en) | Glycogen phosphorylase inhibitor | |
WO2020248964A1 (en) | Use of rhus chinensis fruit in preparation of drugs for treatment and/or prevention of hepatic fibrosis | |
CN105617326A (en) | Method for preparing pharmaceutical composition for preventing and treating acute myocardial infarction | |
US9682117B2 (en) | Extract of zingiber zerumbet for relieving symptoms of diabetic retinopathy | |
WO2016131320A1 (en) | Use of nadph in preparing medicines for treatment of heart diseases | |
JP2010043036A (en) | Saccharometabolism promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |